TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion
ASND0029
Phase 2 small_molecule active
Quick answer
TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active